| Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice N Nishiyama, S Okazaki, H Cabral, M Miyamoto, Y Kato, Y Sugiyama, ... Cancer research 63 (24), 8977-8983, 2003 | 801 | 2003 |
| Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab K Yonesaka, K Zejnullahu, I Okamoto, T Satoh, F Cappuzzo, J Souglakos, ... Science translational medicine 3 (99), 99ra86-99ra86, 2011 | 728 | 2011 |
| Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population H Matsuo, T Takada, K Ichida, T Nakamura, A Nakayama, Y Ikebuchi, ... Science translational medicine 1 (5), 5ra11-5ra11, 2009 | 507 | 2009 |
| LUX-Lung 4: a phase II trial of afatinib in patients with advanced non–small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both N Katakami, S Atagi, K Goto, T Hida, T Horai, A Inoue, Y Ichinose, ... Journal of Clinical Oncology 31 (27), 3335-3341, 2013 | 416 | 2013 |
| Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non–small-cell lung cancer H Kimura, K Kasahara, M Kawaishi, H Kunitoh, T Tamura, B Holloway, ... Clinical Cancer Research 12 (13), 3915-3921, 2006 | 407 | 2006 |
| Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin K Kasahara, Y Fujiwara, K Nishio, T Ohmori, Y Sugimoto, K Komiya, ... Cancer research 51 (12), 3237-3242, 1991 | 349 | 1991 |
| Protein adsorption of ultrafine metal oxide and its influence on cytotoxicity toward cultured cells M Horie, K Nishio, K Fujita, S Endoh, A Miyauchi, Y Saito, H Iwahashi, ... Chemical research in toxicology 22 (3), 543-553, 2009 | 343 | 2009 |
| Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor H Kimura, K Sakai, T Arao, T Shimoyama, T Tamura, K Nishio Cancer science 98 (8), 1275-1280, 2007 | 325 | 2007 |
| Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment K Haratani, H Hayashi, T Tanaka, H Kaneda, Y Togashi, K Sakai, ... Annals of oncology 28 (7), 1532-1539, 2017 | 303 | 2017 |
| Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung … K Goto, Y Ichinose, Y Ohe, N Yamamoto, S Negoro, K Nishio, Y Itoh, ... Journal of Thoracic Oncology 7 (1), 115-121, 2012 | 282 | 2012 |
| Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) H Kimura, M Suminoe, K Kasahara, T Sone, T Araya, S Tamori, F Koizumi, ... British journal of cancer 97 (6), 778-784, 2007 | 281 | 2007 |
| The Japan multi-institutional collaborative cohort study (J-MICC Study) to detect gene-environment interactions for cancer. N Hamajima Asian Pacific journal of cancer prevention: APJCP 8 (2), 317-323, 2007 | 259 | 2007 |
| Efficient implementation of the nonequilibrium Green function method for electronic transport calculations T Ozaki, K Nishio, H Kino Physical Review B—Condensed Matter and Materials Physics 81 (3), 035116, 2010 | 258 | 2010 |
| Turning point in apoptosis/necrosis induced by hydrogen peroxide Y Saito, K Nishio, Y Ogawa, J Kimata, T Kinumi, Y Yoshida, N Noguchi, ... Free radical research 40 (6), 619-630, 2006 | 244 | 2006 |
| FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth H Kaneda, T Arao, K Tanaka, D Tamura, K Aomatsu, K Kudo, K Sakai, ... Cancer research 70 (5), 2053-2063, 2010 | 233 | 2010 |
| Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth M Hirama, F Takahashi, K Takahashi, S Akutagawa, K Shimizu, S Soma, ... Cancer letters 198 (1), 107-117, 2003 | 233 | 2003 |
| Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2 T Ohmori, ER Podack, K Nishio, M Takahashi, Y Miyahara, Y Takeda, ... Biochemical and biophysical research communications 192 (1), 30-36, 1993 | 230 | 1993 |
| EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first-or third-generation TKIs Y Kobayashi, Y Togashi, Y Yatabe, H Mizuuchi, P Jangchul, C Kondo, ... Clinical cancer research 21 (23), 5305-5313, 2015 | 224 | 2015 |
| FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer K Tamura, C Shimizu, T Hojo, S Akashi-Tanaka, T Kinoshita, K Yonemori, ... Annals of Oncology 22 (6), 1302-1307, 2011 | 214 | 2011 |
| Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer K Takezawa, I Okamoto, W Okamoto, M Takeda, K Sakai, S Tsukioka, ... British journal of cancer 104 (10), 1594-1601, 2011 | 211 | 2011 |
